Filing Flows › Rigel Pharmaceuticals (RIGL) › Q2 2026 › vs Q1 2026
Rigel Pharmaceuticals (RIGL) Q2 2026 vs Q1 2026 (quarter over quarter)
Rigel Pharmaceuticals's revenue rose $19.9M (+34%) from $58.8M in Q1 2026 to $78.7M in Q2 2026. Operating margin 30.0% against 20.2% (+9.7 pts).
Rigel Pharmaceuticals, Q2 2026: revenue $78.7M (-23% year over year), operating margin 30.0%, net earnings $17.3M, operating cash flow $30.7M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 30.0% | 20.2% | +9.7 pts |
| Net margin | 22.0% | 14.7% | +7.3 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $78.7M | $58.8M | $19.9M | +34% |
| Operating profit | $23.6M | $11.9M | $11.7M | +98% |
| Costs & expenses | $55.1M | $46.9M | $8.2M | +17% |
| Pre-tax earnings | $23.6M | $11.7M | $11.9M | +102% |
| Cost of revenue | $8.5M | $4.6M | $3.9M | +85% |
| Research & development | $14.0M | $11.7M | $2.3M | +20% |
| SG&A | $32.6M | $30.7M | $2.0M | +6% |
| Net earnings | $17.3M | $8.7M | $8.6M | +100% |
| Income tax | $6.3M | $3.0M | $3.3M | +110% |
| Depreciation & amortization | $848K | $597K | $251K | +42% |
| Share-based compensation | $6.8M | $3.5M | $3.4M | +98% |
| Working capital & other | $5.7M | −$10.0M | $15.7M | — |
| Operating cash flow | $30.7M | $2.7M | $27.9M | 11× |
Questions
How much did Rigel Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Rigel Pharmaceuticals's revenue rose $19.9M (+34%) from $58.8M in Q1 2026 to $78.7M in Q2 2026. Operating margin 30.0% against 20.2% (+9.7 pts).